postoperative aspiration pneumonia among adults using glp-1 receptor agonists No link seen between preop agonist use and postop Mapping the effectiveness and risks

Summary GLP-1 RAs offer a multifaceted therapeutic strategy in PD, targeting both central neurodegenerative processes and peripheral metabolic dysfunction

Delve into the perspectives of employers and health plans on obesity, GLP-1 coverage rates, and concerns about off-label use.

See how GLP-1s are reshaping diabetes & obesity care.

Importantly, increasing the endogenous production of GLP-1 by different mechanisms or by increasing the number of intestinal L-cells that tend to produce this hormone may be another effective therapeutic approach to managing T2DM

Materials and Methods We used mathematical modeling and simulation of semaglutide and tirzepatide